LEUKEMIA LYMPHOMA someday iq SOCIETY LLS's impact Who We Are The Leukemia & Lymphoma Society® (LLS) exists to find cures and ensure access to treatments for all blood cancer patients. LLS is the world's largest voluntary health agency dedicated to blood cancers. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care. What We Do Invest in blood cancer research: LLS has invested more than $1 billion in blood cancer research, approximately $67.2 million in fiscal year 2015 alone. Early research funded by LLS played a role in advances such as the discovery and development of chemotherapy and bone marrow and stem cell transplantation. More recent research has resulted in new, targeted oral therapies and immunotherapies. From 2000 through 2015, more than 40 percent of new anti-cancer drugs were FDA approved for blood cancer patients -- more first-ever approvals than for any other group of cancers -- and many of these were advanced with funding from LLS. Some therapies are even helping patients with other cancers and other serious, nonmalignant diseases. For example, rituximab is now also FDA-approved for use in patients with some autoimmune diseases, including rheumatoid arthritis. LLS supports the world's best and brightest academic researchers to address these urgent, unmet needs. We provide funding across the continuum from basic and translational research through clinical trials, from bench to bedside. Recognizing that therapies were not getting to patients fast enough, we created the Therapy Acceleration Program ®, supporting applied research and forging collaborations with biotechnology companies to help bridge the gap between academic discovery and succ